Skip to main content
Premium Trial:

Request an Annual Quote

Millennium s CTO Moves to Oxford Bioscience Partners

NEW YORK, July 1 - Millennium Pharmaceuticals' chief technology officer, Mike Pavia, will be leaving the company at the end of the week.


Pavia, who spent five years with the company, will become entrepreneur-in-residence at Oxford Bioscience Partners, he said in a recent e-mail message. He also will remain a consultant to Millennium.


"It's time to go out and help incubate the next generation of technologies," Pavia said.


Allan Marchington, senior vice president of productivity, will take over Pavia's responsibilities.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.